In vivo and non-invasive detection of the effects of the use of products on hyaluronic acid in human skin

• Grant number: 21/14696-3
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: May 01, 2022
• End date: April 30, 2024
• Field of knowledge: Engineering - Biomedical Engineering
• Principal Investigator: Lázaro Pinto Medeiros Neto
• Grantee: Lázaro Pinto Medeiros Neto
• Company: Probes Inovação e Desenvolvimento Tecnológico Ltda. - ME
• CNAE: Pesquisa e desenvolvimento experimental em ciências físicas e naturais
• City: São José dos Campos
• Pesquisadores principais: Airton Abrahao Martin
• Associated researchers: Felipe Bachion de Santana ; Gustavo Carlos da Silva ; Lívia Assis Garcia ; Priscila Pereira Fávero
• Associated research grant: 20/00928-7 - Development of an in vivo and non-invasive process for quantifying hyaluronic acid in human skin, AP.PIPE
• Associated scholarship(s): 23/10893-4 - In vivo and non-invasive detection of the effects of product use on hyaluronic acid in human skin., BP.TT; 22/13020-9 - In vivo and non-invasive detection of the effects of the use of products on hyaluronic acid in human skin., BP.TT; 22/03955-0 - In vivo and non-invasive detection of the effects of the use of products on hyaluronic acid in human skin, BP.PIPE

Abstract

Hyaluronic acid (HA) is a glycosaminoglycan in the skin, whose function is to ensure elasticity and firmness, by filling intracellular spaces, providing a youthful appearance. Monitoring HA in human skin in vivo and without invasive procedures is of great commercial importance, as it allows the acquisition of specific information related to the role of HA in the skin aging process, promoting the development of new innovative and more effective cosmetic products. This research project proposes the evaluation of the effects of using anti-aging products on endogenous HA, using the process developed during PIPE-Phase 1. In addition, it proposes the quantification of endogenous HA with other cellular markers in skin biopsies obtained during phase 1 of the study, allowing a pattern for the presence of HA in each skin layer. Briefly, the in vivo skin of study participants in different age groups will be evaluated by the confocal Raman spectroscopy (CRS), before and after using the test product. Analyzes will be performed at baseline and after thirty (T30), sixty (T60) and ninety (T90) days of product use. In addition, in order to establish a detailed amount of HA in the skin layers (stratum corneum, granular, spinous, germinal and dermis) new markers for HA will be used in the skin samples obtained during phase 1. It is expected, in this phase 2 study, that the CRS will identify the changes caused by the use of products that aim to delay aging. As a quick, non-invasive and in vivo process for evaluating HA using CRS was developed during PIPE-Phase 1, it is believed that this process becomes viable for companies that need to validate the effect of their products. (AU)